In a phase 2 trial involving 187 patients with cancer cachexia and elevated GDF15 levels, ponsegromab enabled patients to regain body weight within 12 weeks, with improvements in appetite, physical activity levels, and skeletal muscle mass [193]. Here, GDF15 is linked to Cachexia.